Media stories about Emergent Biosolutions (NYSE:EBS) have been trending somewhat negative on Thursday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of -0.02 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.9135668653555 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Emergent Biosolutions (NYSE EBS) opened at $49.83 on Thursday. The company has a market capitalization of $2,050.00, a P/E ratio of 31.14, a PEG ratio of 0.99 and a beta of 1.29. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a twelve month low of $27.94 and a twelve month high of $50.14.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.41 by $0.32. The company had revenue of $149.43 million during the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 EPS. analysts forecast that Emergent Biosolutions will post 1.66 earnings per share for the current year.
In other news, CEO Daniel Abdun-Nabi sold 31,508 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.77, for a total value of $1,347,597.16. Following the completion of the sale, the chief executive officer now owns 215,642 shares of the company’s stock, valued at approximately $9,223,008.34. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Fuad El-Hibri sold 47,983 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $41.88, for a total value of $2,009,528.04. Following the completion of the sale, the chairman now directly owns 1,550,216 shares of the company’s stock, valued at approximately $64,923,046.08. The disclosure for this sale can be found here. In the last three months, insiders sold 206,329 shares of company stock valued at $8,892,362. 16.50% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “Emergent Biosolutions (EBS) Receiving Somewhat Negative News Coverage, Accern Reports” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2018/01/18/emergent-biosolutions-ebs-receiving-somewhat-negative-news-coverage-accern-reports.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.